Trial Profile
A Phase 3b Study of 2 Treatment Durations of Telaprevir, Peg-IFN (Pegasys), and Ribavirin (Copegus) in Treatment-Naive and Prior Relapser Subjects With Genotype 1 Chronic Hepatitis C and IL28B CC Genotype.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Telaprevir (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Registrational; Therapeutic Use
- Acronyms CONCISE
- Sponsors Vertex Pharmaceuticals
- 26 Jan 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
- 26 Feb 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 08 Jul 2013 Planned end date changed from 1 Dec 2012 to 1 Sep 2013 as reported by ClinicalTrials.gov record.